Ocriplasmin Gets EU Nod for Treating Vitreomacular Traction

by Kathy Jones on  March 19, 2013 at 9:23 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The European Commission has approved the use of ocriplasmin for treating vitreomacular traction (VMT) in the European Union.
 Ocriplasmin Gets EU Nod for Treating Vitreomacular Traction
Ocriplasmin Gets EU Nod for Treating Vitreomacular Traction

Ocriplasmin has been developed by ThromboGenics in collaboration with Novartis and will be sold under the brand name Jetrea. VMT is an age-related and progressive condition which could result in severe eye damage.

The drug has been approved for treating VMT when it is associated with a macular hole with a diameter of 400 ĩm or less.

ThromboGenics will be paid €45 million by Alcon, a subsidiary unit of Novartis, with a similar payment to be made with the first sale of the drug. Around 250,000-300,000 patients in Europe are reported to suffer from VMT with the current treatment involving a 'watchful process' until the patient is eligible for surgery.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Introduction To Physiotherapy Types of Physiotherapy Traction For Lumbar Pain Modified Atkins Diet: All You Need to Know 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive